A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-10

Study Completion Date

2008-05-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study will investigate the pharmacodynamics of a dual pharmacophore in which a combination of GSK961081 and Propanolol is used to give a total effect of bronchodilation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.

NCT00674817

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Study of GSK961081 in Healthy Volunteer Subjects

NCT00887406

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE1

A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients

NCT00478738

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

NCT01449799

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE1

Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

NCT00376714

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All subjects

Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.

Group Type EXPERIMENTAL

GSK961081

Intervention Type DRUG

GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.

GSK961081 matching placebo

Intervention Type DRUG

GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.

Propranolol

Intervention Type DRUG

Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.

Propranolol matching placebo

Intervention Type DRUG

Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK961081

GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.

Intervention Type DRUG

GSK961081 matching placebo

GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.

Intervention Type DRUG

Propranolol

Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.

Intervention Type DRUG

Propranolol matching placebo

Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult males aged between 18 and 50 years.
* Body mass index within the range 19-29.9 kg/m2.
* FEV1 ≥ 80% predicted and a FEV1/ Forced Vital Capacity (FVC) ratio ≥ 0.7
* Signed and dated written informed consent is obtained from the subject
* The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions.
* The subject has an increase in sGAW of ≥15% over pre-dose baseline within 2 h of administration of 400 µg salbutamol by MDI inhaler at screening or in the 3 months before screening.
* The subject has an increase in sGAW of ≥25% over pre-dose baseline within 2 h following 80 µg ipratropium bromide at screening or in the 3 months before screening.
* Subjects who are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of ≥ 10 pack years.

Exclusion Criteria

* Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead or Holter).
* A history of respiratory disease (i.e. history of asthmatic symptoms).
* Clinically significant abnormal 12 lead ECG at
* A subject in whom ipratropium bromide, salbutamol or propranolol are contraindicated.
* A supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening.
* A supine mean heart rate outside the range 45-90 beats per minute (bpm) at screening.
* The subject has donated a unit of blood within the 56 days or intends to donate within 56 days after completing the study.
* The subject is currently taking regular (or course of) medication whether prescribed or not (with the exception of contraceptives, including vitamins and herbal remedies such as St John's Wort.
* The subject has used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (which ever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and medical monitor the medication will not interfere with the study procedures or compromise subject safety.
* The subject has participated in a clinical study with a New Chemical Entity (NCE) within the past 3 months.
* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
* The subject is infected with the Hepatitis B, Hepatitis C, or HIV virus.
* The subject has a positive pre-study urine cotinine/ breath carbon monoxide test, urine drug/urine alcohol screen.
* A history of regular alcohol consumption exceeding weekly intake of alcohol greater than 28 units for males, or an average daily intake of greater than 4 units.
* Are unable to use the inhaler correctly.
* The subject has a history of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation.
* The subject has had a lower respiratory tract infection within 4 weeks of study start.
* Subject is unable to perform the sGAW measurements

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Harrow, Middlesex, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.